Hatakeyama Shingo, Toikawa Terumasa, Okamoto Akiko, Yamamoto Hayato, Imanishi Kengo, Okamoto Teppei, Tokui Noriko, Suzuki Yuichiro, Sugiyama Naoki, Imai Atsushi, Hashimoto Yasuhiro, Kudo Shigemasa, Yoneyama Takahiro, Koie Takuya, Kamimura Noritaka, Saitoh Hisao, Funyu Tomihisa, Ohyama Chikara
Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, Japan.
Int J Nephrol. 2011;2011:464735. doi: 10.4061/2011/464735. Epub 2011 Nov 20.
Vascular access stenosis is a major complication in hemodialysis patients. We prospectively observed 50 patients in whom 50 nitinol shape-memory alloy-recoverable technology (SMART) stents were used as salvage therapy for recurrent peripheral venous stenosis. Twenty-five stents each were deployed in native arteriovenous fistula (AVF) and synthetic arteriovenous polyurethane graft (AVG) cases. Vascular access patency rates were calculated by Kaplan-Meier analysis. The primary patency rates in AVF versus AVG at 3, 6, and 12 months were 80.3% versus 75.6%, 64.9% versus 28.3%, and 32.3% versus 18.9%, respectively. The secondary patency rates in AVF versus AVG at 3, 6, and 12 months were 88.5% versus 75.5%, 82.6% versus 61.8%, and 74.4% versus 61.8%, respectively. Although there were no statistically significant difference in patency between AVF and AVG, AVG showed poor tendency in primary and secondary patency. The usefulness of SMART stents was limited in a short period of time in hemodialysis patients with recurrent vascular access stenosis.
血管通路狭窄是血液透析患者的主要并发症。我们前瞻性地观察了50例患者,其中50个镍钛诺形状记忆合金可回收技术(SMART)支架被用作复发性外周静脉狭窄的挽救治疗。在自体动静脉内瘘(AVF)和人工动静脉聚氨酯移植物(AVG)病例中分别植入了25个支架。通过Kaplan-Meier分析计算血管通路通畅率。AVF和AVG在3个月、6个月和12个月时的初次通畅率分别为80.3%对75.6%、64.9%对28.3%和32.3%对18.9%。AVF和AVG在3个月、6个月和12个月时的二次通畅率分别为88.5%对75.5%、82.6%对61.8%和74.4%对61.8%。虽然AVF和AVG在通畅率方面没有统计学上的显著差异,但AVG在初次和二次通畅方面显示出较差的趋势。对于复发性血管通路狭窄的血液透析患者,SMART支架在短时间内的有效性有限。